Drugs / ABC/DTG/3TC
ABC/DTG/3TC
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02603120 Comparator | Nov 2015 → May 2017 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABC/DTG/3TC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02603120 ↗ |
| Known as | dolutegravir/abacavir/lamivudine | “dolutegravir/abacavir/lamivudine (DTG/ABC/3TC)” PMID 31430369 ↗ Dec 2019 |
| Known as | DTG/ABC/3TC | “dolutegravir/abacavir/lamivudine (DTG/ABC/3TC)” PMID 31430369 ↗ Dec 2019 |
| Modality | Other / unclassified | “another INSTI-based regimen, co-formulated abacavir, dolutegravir, and lamivudine (ABC/DTG/3TC).” PMID 29956087 ↗ Oct 2018 |
| Route | Oral | “600/50/300 mg FDC tablets administered orally once daily without regard to food” NCT02603120 ↗ |